Navigation Links
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Date:3/12/2009

CHADDS FORD, Pa., March 12 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) and its majority-owned subsidiary Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the complete response submission to the new drug application for NEBIDO(R) (testosterone undecanoate) intramuscular injection, an investigational testosterone preparation for the treatment of male hypogonadism. FDA is targeting September 2, 2009 as the action date for a decision on this application.

Endo's president and CEO, David Holveck, stated: "We are pleased with the FDA's action and congratulate the NEBIDO development team on reaching this milestone. We look forward to receiving the FDA's decision on the NEBIDO marketing application in September."

About NEBIDO

NEBIDO is a novel, long-acting injectable testosterone preparation for the treatment of male hypogonadism. NEBIDO was licensed by BayerSchering Pharma AG to Indevus Pharmaceuticals, a majority interest in which Endo acquired earlier this year. If approved, NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. NEBIDO is currently marketed by BayerSchering and its partners in Europe and other territories.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunction, musc
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Elekta (NSE:EKTAb) and ... The Christie NHS Foundation Trust ( Manchester, UK ... consortium whose mission is to develop the clinical value ... therapy system. Such a system would, in principle, improve ... targets. "The Christie was an essential ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
(Date:7/22/2014)...  July 22, 2014 The ... Reuters , the world,s leading provider of ... announced Cortellis Clinical Trials Intelligence , ... industry-first milestone with the documentation of more ... professionals with greater and quicker access to ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Dec. 7, 2010 LABS Inc., the premier transplant ... that Kevin M. Smith, Chief Operating Officer of the ... has joined the company,s Board of Directors.  Smith brings ... industries. In addition to his current role ...
... 80 percent of the surgeries performed in the U.S. put patients ... a brain monitor is not used by the anesthesiologist. ... book recently published by Dr. Barry Friedberg, an acclaimed anesthesiologist who ... in Michael Jackson,s death. "The simple use of a ...
Cached Medicine Technology:LABS Inc. Adds Life Sciences Industry Veteran Kevin M. Smith to Board of Directors 2Michael Jackson's Death Could Have Been Avoided With a Brain Monitor Says Anesthesiologist 2
(Date:7/22/2014)... Dr. Dental is excited to announce the redesign of ... mind, one of the main differences from the old website ... very easy. Dr. Dental is renowned for having exceptional customer ... affordable, convenient and fun, and the new website mirrors these ... scheduling system right on the home page where a visitor ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's ... McPhearson, an insurance veteran with more than 15 years ... be based in the company's Chicago office. , UBA ... Les chose to accept this important, strategic position with ... many challenges facing UBA and its Partners as we ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... that break up blood clots deep in the veins of ... However, one results in a greater risk of bleeding and ... the other treatment, a new study finds. The standard ... (DVT) -- is blood-thinning medications and compression stockings. The other, ...
(Date:7/22/2014)... of Hematology (ASH) will honor Michael DeBaun, MD, MPH, ... Hebbel, MD, of the University of Minnesota Medical School ... their significant research advances in the area of sickle ... the late Ernest Beutler, MD, a past president of ... a two-part lectureship that recognizes major translational advances related ...
(Date:7/22/2014)... E. Marc, Ph.D., director of research at the University ... named by the International Society of Eye Research (ISER) ... Foundation,s 2014 Paul Kayser International Award in Retina Research., ... who has made a significant contribution to the understanding ... presented this week at the ISER Biennial Meeting in ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Fishies is Nordic Naturals newest product for children, the "ultimate ... tasting natural tangerine flavor. Perfect for two-year-olds and up, Nordic ... oil from anchovies and sardines, two sustainable sources of high ... 455 mg of fish oil and offers 136 mg of ...
... Jourdan Urbach, a senior at Roslyn High School, is at ... only 12 seniors nationwide to be named a "national" Toyota Community ... than 8,000 seniors from across the country were nominated by their ... year, honors the top 100 students in the U.S. who are ...
... 23 The European diabetes diagnostics market is poised ... (POC) tests offering tremendous growth potential. Heightened efforts to ... a key driver in market development. For instance, limited ... However, this challenge will be curtailed with more education ...
... ... for the Study of Subtle Energies & Energy Medicine will hold their 19th annual conference ... ... professionals will be interested in attending the 19th annual ISSSEEM Conference that will begin with ...
... ... , ... 23, 2009 -- Big Case Marketing, the global leader in marketing for dentists, dental marketing ... a Boston based coaching and consulting firm for dentists with advanced clinical training, has announced ...
... Dr. Steven Shoshany ... www.LivingwellNewYork.com , to coincide with an exciting new direction he is taking with his office ... ... Chiropractic care in New York City for more than 13 years in his SOHO office. He ...
Cached Medicine News:Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3Health News:19th Annual ISSSEEM Conference to Have Richard Bartlett to Discuss the Physics of Miracles: Connecting to the Quantum Field 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2
Calcitonin RIA Kit...
... 1200's speed and accuracy allow clinical ... a timely manner - something everyone ... patients. In fact, the Rapidlab 1200 ... just one minute. Its maintenance-free, cartridge-based ...
... The Dornier Medilas D Fibertom is a 60 ... nm wavelength. The use of Diode Power Bar ... system ideal for endovenous laser treatment for varicose ... Medilas D Fibertom also includes unique safety features ...
... test studies the characteristic axies of ... however this 28 hue test ... Case comes with a transparent base ... includes laminated scoring template (approx 8 ...
Medicine Products: